Docetaxel, Carboplatin, Trastuzumab and Bevacizumab (TCH+B) For Early-Stage HER-2/Neu(+) Breast Cancer and Bone Marrow Micrometastases

NCT00949247 EARLY_PHASE1 COMPLETED

RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab and bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving chemotherapy together with monoclonal antibody therapy may kill more tumor cells. PURPOSE: This clinical trial is studying how well giving docetaxel and carboplatin together with trastuzumab and bevacizumab works in treating patients with stage I, stage II, or stage III breast cancer and bone marrow micrometastases.

Details

Lead sponsor	Case Comprehensive Cancer Center
Phase	EARLY_PHASE1
Status	COMPLETED
Enrolment	20
Start date	2009-12
Completion	2013-01

Conditions

• Breast Cancer

Interventions

• bevacizumab
• trastuzumab
• carboplatin
• docetaxel
• laboratory biomarker analysis

Primary outcomes

• Proportion of patients who have a complete response in bone marrow. — at 4 weeks after completing 6 courses of therapy

Countries

United States